Analysis Article • May 01

Over the last 7 days, the Clinical Research and Equipment industry has dropped 2.8%, driven by AddLife declining 2.7%. However, the industry is down 13% over the past year. As for the next few years, earnings are expected to grow by 28% per annum.
Has the Swedish Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 23 Jun 2026 | SEK 29.0b | SEK 14.6b | -SEK 871,304,353.00 | 33.6x | -33.3x | 2x |
| Thu, 21 May 2026 | SEK 29.9b | SEK 14.6b | -SEK 850,163,077.00 | 37.4x | -35.1x | 2x |
| Sat, 18 Apr 2026 | SEK 31.3b | SEK 14.6b | -SEK 971,664,077.00 | 36.3x | -32.2x | 2.1x |
| Mon, 16 Mar 2026 | SEK 26.9b | SEK 14.6b | -SEK 838,374,077.00 | 32.4x | -32.1x | 1.8x |
| Wed, 11 Feb 2026 | SEK 28.6b | SEK 14.9b | -SEK 555,615,427.00 | 34.3x | -51.4x | 1.9x |
| Fri, 09 Jan 2026 | SEK 30.7b | SEK 14.9b | -SEK 744,515,427.00 | 48x | -41.3x | 2.1x |
| Sun, 07 Dec 2025 | SEK 33.4b | SEK 14.9b | -SEK 744,515,427.00 | 55.6x | -44.9x | 2.3x |
| Tue, 04 Nov 2025 | SEK 37.3b | SEK 14.8b | SEK 117.3m | 55.5x | 317.7x | 2.5x |
| Thu, 02 Oct 2025 | SEK 34.0b | SEK 14.7b | SEK 61.3m | 58.3x | 554.8x | 2.3x |
| Sat, 30 Aug 2025 | SEK 34.9b | SEK 14.7b | SEK 59.9m | 58.4x | 583.5x | 2.4x |
| Mon, 28 Jul 2025 | SEK 36.7b | SEK 14.8b | SEK 186.0m | 65.8x | 197.2x | 2.5x |
| Wed, 25 Jun 2025 | SEK 45.2b | SEK 16.6b | SEK 405.8m | 70.6x | 111.3x | 2.7x |
| Fri, 23 May 2025 | SEK 44.9b | SEK 16.6b | SEK 405.7m | 44.5x | 110.7x | 2.7x |
| Sun, 20 Apr 2025 | SEK 36.9b | SEK 16.6b | SEK 609.4m | 39.6x | 60.5x | 2.2x |
| Tue, 18 Mar 2025 | SEK 38.1b | SEK 16.6b | SEK 614.9m | 38.2x | 61.9x | 2.3x |
| Thu, 13 Feb 2025 | SEK 43.4b | SEK 17.0b | -SEK 1,038,511,426.00 | 42.5x | -41.8x | 2.6x |
| Sat, 11 Jan 2025 | SEK 43.7b | SEK 16.7b | -SEK 1,152,911,426.00 | 49.5x | -37.9x | 2.6x |
| Mon, 09 Dec 2024 | SEK 43.4b | SEK 16.7b | -SEK 1,154,323,426.00 | 50.1x | -37.6x | 2.6x |
| Wed, 06 Nov 2024 | SEK 43.5b | SEK 16.8b | -SEK 958,019,827.00 | 51.1x | -45.4x | 2.6x |
| Fri, 04 Oct 2024 | SEK 47.6b | SEK 16.7b | -SEK 988,175,491.00 | 58.9x | -48.2x | 2.9x |
| Sun, 01 Sep 2024 | SEK 49.5b | SEK 16.7b | -SEK 987,374,492.00 | 62.9x | -50.1x | 3x |
| Tue, 30 Jul 2024 | SEK 49.5b | SEK 16.7b | -SEK 1,128,120,510.00 | 62.2x | -43.9x | 3x |
| Thu, 27 Jun 2024 | SEK 41.1b | SEK 16.3b | -SEK 1,188,686,510.00 | 53.2x | -34.6x | 2.5x |
| Sat, 25 May 2024 | SEK 42.2b | SEK 16.3b | -SEK 1,188,529,510.00 | 60.1x | -35.5x | 2.6x |
| Mon, 22 Apr 2024 | SEK 36.6b | SEK 16.0b | -SEK 1,122,732,213.00 | 34.3x | -32.6x | 2.3x |
| Wed, 20 Mar 2024 | SEK 38.5b | SEK 16.0b | -SEK 1,123,139,210.00 | 33.9x | -34.3x | 2.4x |
| Fri, 16 Feb 2024 | SEK 39.8b | SEK 15.8b | -SEK 1,473,823,683.00 | 56.3x | -27x | 2.5x |
| Sun, 14 Jan 2024 | SEK 38.3b | SEK 15.5b | -SEK 1,393,723,683.00 | 47x | -27.5x | 2.5x |
| Tue, 12 Dec 2023 | SEK 36.1b | SEK 15.5b | -SEK 1,393,723,683.00 | 43.8x | -25.9x | 2.3x |
| Thu, 09 Nov 2023 | SEK 30.9b | SEK 15.4b | -SEK 1,256,647,710.00 | 33.9x | -24.6x | 2x |
| Sat, 07 Oct 2023 | SEK 26.1b | SEK 15.1b | -SEK 1,134,516,711.00 | 36.2x | -23x | 1.7x |
| Mon, 04 Sep 2023 | SEK 30.6b | SEK 15.1b | -SEK 1,134,263,831.00 | 42.1x | -27x | 2x |
| Wed, 02 Aug 2023 | SEK 32.6b | SEK 15.1b | -SEK 213,871,038.00 | 47x | -152.3x | 2.2x |
| Fri, 30 Jun 2023 | SEK 35.6b | SEK 14.6b | -SEK 172,476,038.00 | 36.1x | -206.6x | 2.4x |
-206.6x
How does Swedish Clinical Research and Equipment compare with similar industries?
| SE Market | 0.19% | |
| Healthcare | -1.94% | |
| Life Sciences | -2.83% | |
| Clinical Research and Equipment | -2.83% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BICO BICO Group | SEK 16.56 | 1.5% +SEK 16.9m | -50.1% | PS0.8x | |
| ATANA Attana | SEK 0.005 | 25.0% +SEK 2.6m | -75.0% | PS4.5x | |
| PRO Promimic | SEK 10.60 | 1.0% +SEK 1.9m | -41.4% | PS4x | |
| LEVBIO Level Bio | SEK 0.30 | 3.5% +SEK 684.0k | 7.2% | PS0.6x |